Szabó C, Southan G J, Thiemermann C
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, United Kingdom.
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12472-6. doi: 10.1073/pnas.91.26.12472.
Enhanced formation of nitric oxide (NO) by both the constitutive and the inducible isoforms of NO synthase (NOS) has been implicated in the pathophysiology of a variety of diseases, including circulatory shock. Non-isoform-selective inhibition of NO formation, however, may lead to side effects by inhibiting the constitutive isoform of NOS and, thus, the various physiological actions of NO. S-Methylisothiourea sulfate (SMT) is at least 10- to 30-fold more potent as an inhibitor of inducible NOS (iNOS) in immunostimulated cultured macrophages (EC50, 6 microM) and vascular smooth muscle cells (EC50, 2 microM) than NG-methyl-L-arginine (MeArg) or any other NOS inhibitor yet known. The effect of SMT on iNOS activity can be reversed by excess L-arginine in a concentration-dependent manner. SMT (up to 1 mM) does not inhibit the activity of xanthine oxidase, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide dismutase. SMT is equipotent with MeArg in inhibiting the endothelial, constitutive isoform of NOS in vitro and causes increases in blood pressure similar to those produced by MeArg in normal rats. SMT, however, dose-dependently reverses (0.01-3 mg/kg) the hypotension and the vascular hyporeactivity to vasoconstrictor agents caused by endotoxin [bacterial lipopolysaccharide (LPS), 10 mg/kg, i.v.] in anesthetized rats. Moreover, therapeutic administration of SMT (5 mg/kg, i.p., given 2 hr after LPS, 10 mg/kg, i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS. SMT (1 mg/kg, i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg, i.p.). Thus, SMT is a potent and selective inhibitor of iNOS and exerts beneficial effects in rodent models of septic shock. SMT, therefore, may have considerable value in the therapy of circulatory shock of various etiologies and other pathophysiological conditions associated with induction of iNOS.
一氧化氮合酶(NOS)的组成型和诱导型同工型增强一氧化氮(NO)的生成,这与包括循环性休克在内的多种疾病的病理生理学有关。然而,对NO生成的非同工型选择性抑制可能会通过抑制NOS的组成型同工型,进而抑制NO的各种生理作用而导致副作用。硫酸S-甲基异硫脲(SMT)作为免疫刺激培养巨噬细胞(半数有效浓度为6 microM)和血管平滑肌细胞(半数有效浓度为2 microM)中诱导型NOS(iNOS)的抑制剂,其效力至少比N-甲基-L-精氨酸(MeArg)或任何其他已知的NOS抑制剂强10至30倍。过量的L-精氨酸可浓度依赖性地逆转SMT对iNOS活性的影响。SMT(高达1 mM)不抑制黄嘌呤氧化酶、黄递酶、乳酸脱氢酶、单胺氧化酶、过氧化氢酶、细胞色素P450或超氧化物歧化酶的活性。在体外,SMT抑制NOS内皮组成型同工型的效力与MeArg相当,且在正常大鼠中引起的血压升高与MeArg相似。然而,在麻醉大鼠中,SMT(0.01 - 3 mg/kg)剂量依赖性地逆转由内毒素[细菌脂多糖(LPS),10 mg/kg,静脉注射]引起的低血压和血管对血管收缩剂的低反应性。此外,治疗性给予SMT(5 mg/kg,腹腔注射,在LPS 10 mg/kg腹腔注射后2小时给予)可减轻血浆丙氨酸和天冬氨酸转氨酶、胆红素和肌酐的升高,并且在给予LPS 6小时后测量时还可预防低钙血症。SMT(1 mg/kg,腹腔注射)可提高高剂量LPS(60 mg/kg,腹腔注射)处理的小鼠的24小时存活率。因此,SMT是一种有效的iNOS选择性抑制剂,在脓毒性休克的啮齿动物模型中发挥有益作用。因此,SMT在治疗各种病因的循环性休克以及与iNOS诱导相关的其他病理生理状况方面可能具有相当大的价值。